Savara Inc Share-based Payment Arrangement, Expense, after Tax
Savara Inc (SVRA) reported Share-based Payment Arrangement, Expense, after Tax of $365.14 thousand for the 3-month period ending 2013-06-30, per its 10-Q filed 2013-08-05.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax · last filed 2013-08-05
- Savara Inc share-based payment arrangement, expense, after tax for the quarter ending 2013-06-30 was $365.14K, a 8.41% increase year-over-year.
- Savara Inc share-based payment arrangement, expense, after tax for the quarter ending 2013-03-31 was $351.56K, a 6.87% decline year-over-year.
- Savara Inc share-based payment arrangement, expense, after tax for the quarter ending 2012-12-31 was $385.46K, a 15.98% increase year-over-year.
- Savara Inc share-based payment arrangement, expense, after tax for the quarter ending 2012-09-30 was $359.54K, a 10.61% increase year-over-year.
- Savara Inc share-based payment arrangement, expense, after tax for fiscal 2012 was $1.46M, a 68.50% increase from fiscal 2011.
- Savara Inc share-based payment arrangement, expense, after tax for fiscal 2011 was $866.05K.
| Period end | Share-based Payment Arrangement, Expense, after Tax 3 month | Share-based Payment Arrangement, Expense, after Tax 6 month | Share-based Payment Arrangement, Expense, after Tax 9 month | Share-based Payment Arrangement, Expense, after Tax 12 month |
|---|---|---|---|---|
| 2013-06-30 | $365.14K 10-Q · filed 2013-08-05 | $716.69K 10-Q · filed 2013-08-05 | $1.10M derived: sum of 3 quarters · filed 2013-08-05 | $1.46M derived: sum of 4 quarters · filed 2013-08-05 |
| 2013-03-31 | $351.56K 10-Q · filed 2013-05-15 | $737.01K derived: sum of 2 quarters · filed 2013-05-15 | $1.10M derived: sum of 3 quarters · filed 2013-05-15 | $1.43M derived: sum of 4 quarters · filed 2013-08-05 |
| 2012-12-31 | $385.46K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-19 | $745.00K derived: sum of 2 quarters · filed 2013-03-19 | $1.08M derived: sum of 3 quarters · filed 2013-08-05 | $1.46M 10-K · filed 2013-03-19 |
| 2012-09-30 | $359.54K 10-Q · filed 2012-11-05 | $696.37K derived: sum of 2 quarters · filed 2013-08-05 | $1.07M 10-Q · filed 2012-11-05 | $1.41M derived: sum of 4 quarters · filed 2013-08-05 |
| 2012-06-30 | $336.82K 10-Q · filed 2013-08-05 | $714.33K 10-Q · filed 2013-08-05 | $1.05M derived: sum of 3 quarters · filed 2013-08-05 | $1.37M derived: sum of 4 quarters · filed 2013-08-05 |
| 2012-03-31 | $377.50K 10-Q · filed 2013-05-15 | $709.85K derived: sum of 2 quarters · filed 2013-05-15 | $1.03M derived: sum of 3 quarters · filed 2013-05-15 | $1.11M derived: sum of 4 quarters · filed 2013-05-15 |
| 2011-12-31 | $332.35K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-19 | $657.41K derived: sum of 2 quarters · filed 2013-03-19 | $730.73K derived: sum of 3 quarters · filed 2013-03-19 | $866.05K 10-K · filed 2013-03-19 |
| 2011-09-30 | $325.06K 10-Q · filed 2012-11-05 | $398.38K derived: sum of 2 quarters · filed 2012-11-05 | $533.70K 10-Q · filed 2012-11-05 | |
| 2011-06-30 | $73.32K 10-Q · filed 2012-08-06 | $208.64K 10-Q · filed 2012-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |